Haemonetics Corporation (NYSE:HAE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Haemonetics Corporation (NYSE:HAE) has been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $84.40.

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Barrington Research increased their price objective on Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a report on Monday, January 12th. Finally, Robert W. Baird boosted their target price on Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a report on Monday, December 15th.

Haemonetics Trading Down 0.2%

Shares of NYSE HAE opened at $65.93 on Friday. The business has a 50 day simple moving average of $78.72 and a 200 day simple moving average of $65.57. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of 19.28, a PEG ratio of 1.37 and a beta of 0.29. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts predict that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after acquiring an additional 971 shares during the period. Caxton Associates LLP acquired a new stake in shares of Haemonetics in the first quarter valued at about $216,000. United Services Automobile Association bought a new position in shares of Haemonetics in the first quarter worth about $212,000. Empowered Funds LLC lifted its position in shares of Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after purchasing an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Haemonetics by 6.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after purchasing an additional 9,051 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.